CORPORATION (OTCMKTS:CCYPQ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 18, 2017, RXi Pharmaceuticals Corporation (the “Company”) issued a press release announcing that Pamela Pavco, Ph.D., Chief Development Officer and a named executive officer of the Company, had informed the Company of her intention to retire as an executive officer of the Company on May 19, 2017. Dr. Pavco will continue her role with the Company until the effective date of her retirement and transition to the Company’s Scientific Advisory Board.

In connection with Dr. Pavco’s retirement, Gerrit Dispersyn, Dr. Med. Sc. has been appointed as the Chief Development Officer of the Company effective April 24, 2017.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated April 18, 2017.

*        *        *

2

CORPORATION (OTCMKTS:CCYPQ) Recent Trading Information

CORPORATION (OTCMKTS:CCYPQ) closed its last trading session 00.00000 at 0.00010 with 400 shares trading hands.